A retrospective study to collect the effectiveness and safety data of the past treatment with KUVAN in Chinese patients with HPA caused by BH4 deficiency. The data was collected from relevant past medical history and past clinical and safety assessments.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Diagnosis on BH4 deficiency based on medical history - laboratory testing results indicating sub-type (% in each sub-type) • Incidents and severity of AE reported (% of incident / % of each severity)
Timeframe: 2010-2015
Retrospective KUVAN treatment history - dose (mg/kg/day),
Timeframe: 2010-2015
Retrospective KUVAN treatment history - length of exposure (days)
Timeframe: 2010-2015
Retrospective Baseline Phe concentration ≥ 450 μmol/L - laboratory testing results (μmol/L)
Timeframe: 2010-2015
Number of participants with AE reported (% of patient with AE reported)
Timeframe: 2010-2015
Incidents and severity of AE reported (% of incident / % of each severity)
Timeframe: 2010-2015
Retrospective blood Phe level as indicated in laboratory testing results (μmol/L)
Timeframe: 2010-2015
Retrospective body height as indicated in medical note (cm)
Timeframe: 2010-2015
Retrospective body weight as indicated in medical note (kg)
Timeframe: 2010-2015
Retrospective occipital / frontal circumferences as indicated in medical note (cm)
Timeframe: 2010-2015
Retrospective intelligence development status via China local standard development assessment method (score)
Timeframe: 2010-2015